Q2 FY2026 · ended Jun 30, 2026 · Revenue $151,940, -78.7% YoY · Filed Aug 14, 2026
iSpecimen Inc. (ISPC) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $151,940 and a net loss of $1.4 million. As of Jun 30, 2026 it held $4.4 million in cash and investments and $240,903 in total debt.
Revenue
$151,940
-78.7% vs year-ago quarter
Net income
$-1.36M
-30.1% vs year-ago quarter
Operating cash flow
$-689,625
-258.7% vs year-ago quarter
Free cash flow
$-916,923
+74.4% vs year-ago quarter
EPS
$-0.98
+94.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.52M
-54.5% vs year-ago quarter
Net cash
$4.17M
Q2 FY2026
Operating margin
-2020.0%
TTM
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- ISPC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1558569
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $151,940 | $156,009 | $51,761 | $106,592 | $713,135 |
| Operating income | -$1.4M | -$2.5M | -$2.7M | -$2.8M | -$1.8M |
| Net income | -$1.4M | -$2.3M | -$5.0M | -$2.8M | -$1.0M |
| Diluted EPS | -$0.98 | -$6.66 | -$0.65 | -$0.48 | -$16.78 |
| Operating cash flow | -$689,625 | -$3.4M | -$916,923 | -$2.0M | -$192,234 |
| Free cash flow | — | — | -$916,923 | -$2.0M | -$192,688 |
| Total assets | $7.4M | $6.6M | $9.5M | $9.0M | $6.0M |
| Total liabilities | $5.7M | $5.8M | $6.4M | $5.9M | $5.4M |
| Stockholders' equity | $1.7M | $814,038 | $3.1M | $3.1M | $621,973 |
| Cash and investments | $4.4M | $2.8M | $6.9M | — | — |
| Total debt | $240,903 | $254,989 | $268,798 | $281,436 | $287,885 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Regulation FD disclosure
|
Nov 5, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 10, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 4, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 31, 2026 | Aug 26, 2026 |
All 333 iSpecimen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.